Physician profile
Joan E Siracuse
NPI 1649252925
$6,119.65
in general payments reported to CMS, 2019-2025
26 companies · $40.80 in 2025
The $40.80 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $905 · 2021: $991 · 2022: $1,608 · 2023: $1,099 · 2024: $551 · 2025: $40.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $577.61 | 2019-2023 | Mitraclip |
| Amgen INC. | $543.65 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $500.08 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $468.16 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $456.92 | 2019-2023 | |
| Boston Scientific Corporation | $385.03 | 2019-2024 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $335.85 | 2022-2024 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $313.92 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $307.23 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $289.35 | 2019-2024 | Camzyos, Eliquis |
| Philips North America LLC | $258.42 | 2020-2025 | (Ck7) Extended Holter, Extended Holter |
| Pfizer INC. | $253.06 | 2019-2024 | |
| Amarin Pharma, INC. | $249.10 | 2019-2021 | |
| Astellas Pharma US INC | $236.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.63 | 2019-2023 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $175.68 | 2022-2023 | |
| Esperion Therapeutics, INC. | $145.37 | 2020-2024 | Nexletol |
| Biotronik INC. | $129.07 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.66 | 2022-2024 | Lifevest |
| Medtronic Vascular, INC. | $52.20 | 2019-2020 | |
| Braemar Manufacturing, LLC | $49.28 | 2019 | |
| Cvrx, INC. | $23.57 | 2023-2024 | Barostim Neo System |
| Inspire Medical Systems, INC. | $23.30 | 2023 | Inspire |
| Regeneron Healthcare Solutions, INC. | $16.33 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.67 | 2022 | |
| Ethicon US, LLC | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Siracuse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.